ID: ALA215756

Max Phase: Preclinical

Molecular Formula: C28H27N5O3

Molecular Weight: 481.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)CCCCc1nc2c(=O)n(Cc3ccccc3)nc(C)c2c2cc(-c3ccccc3)nn12

Standard InChI:  InChI=1S/C28H27N5O3/c1-19-26-23-17-22(21-13-7-4-8-14-21)31-33(23)24(15-9-10-16-25(34)36-2)29-27(26)28(35)32(30-19)18-20-11-5-3-6-12-20/h3-8,11-14,17H,9-10,15-16,18H2,1-2H3

Standard InChI Key:  GFDYIUKUGURPBI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 481.56

Molecular Weight (Monoisotopic): 481.2114

AlogP: 4.35

#Rotatable Bonds: 8

Polar Surface Area: 91.38

Molecular Species: NEUTRAL

HBA: 8

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 4.52

CX LogD: 4.52

Aromatic Rings: 5

Heavy Atoms: 36

QED Weighted: 0.24

Np Likeness Score: -1.20

References

1. Giovannoni MP, Vergelli C, Biancalani C, Cesari N, Graziano A, Biagini P, Gracia J, Gavaldà A, Dal Piaz V..  (2006)  Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.,  49  (17): [PMID:16913726] [10.1021/jm060265+]

Source

Source(1):

• Scientific Literature